Purpose-built for TIPS 

Built for lasting performance


The VIATORR® Device allows you to select and maintain the diameter to reach the targeted portal pressure gradient. Choose a device feature to learn more.
VIATORR® Device

Tap a point+in the image to view its details here

supportImage

Showing of

ALTA-recommended for TIPS placement

The American Liver Therapeutic Approaches (ALTA) group recommends "the use of an ePTFE-lined stent graft with controlled expansion, which allows the operator to tailor the amount of portosystemic shunting based on the indication, target gradient and patient comorbidities.”1

Diameter control using Controlled Expansion 

Designed to reach a targeted portal pressure gradient, accurately and consistently to reach an individualized TIPS treatment.

More diameter options = Precision

Accurate diameter controlc = Targeted portal pressure

Tailored diameter to target pressure of the individual patient = Trusted performance and safetyd

Predictable intraoperative experience

The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion offers visualization and GORE® SIM-PULL® Delivery System supporting a predictable intraoperative experience.

Conformability in tortuous anatomy

  • Two - step stent delivery
  • Radiopaque markers
  • Controlled Expansion Sleeve
Illustration of a curved covered stent graft with an uncovered metal mesh extension at one end. A red measurement callout highlights a 6 to 10 mm section along the graft, indicating the adjustable dilatation range.
Comparison image showing five covered stent grafts with uncovered metal mesh extensions, each illustrating a different expansion diameter. The devices are displayed horizontally, demonstrating progressive increases in lumen size.
Illustration of a curved covered stent graft with an uncovered metal mesh extension. An inset magnifies the graft and labels selectable expansion diameters of 6 mm, 7 mm, 8 mm, 9 mm, and 10 mm.

Built for long-term results

 

76%

Two-year primary patency2

The VIATORR® Device was proven to maintain TIPS patency over time in a randomized controlled study (N = 80)2

Built for improved outcomes


Patients treated with the VIATORR® Device have a higher 1-year survival than those treated with non-TIPS therapy.3,4
 
Variceal bleeding outcomes

Early TIPS compared to drug therapy plus endoscopic band ligation (EBL) for variceal bleeding4

 

86%

1-year survival

following early TIPS procedure with the VIATORR® Device, compared to 61% 1-year survival following pharmacotherapy plus endoscopic band ligation (P < 0.001)e,4

97%

1-year control of bleeding

following early TIPS procedure with the VIATORR® Device, compared to 50% 1-year survival following pharmacotherapy plus endoscopic band ligation (P < 0.001)f,4

Not allowed icon

No increase in the risk of hepatic encephalopathy

at 1 year, compared to pharmacotherapy plus endoscopic band ligation (P = 0.13)4

 

 

circle-check-red

Improved survival

TIPS with the VIATORR® Device demonstrated higher transplant-free survival (93%), compared to large volume paracenteses (LVP) and albumin infusion (52%) (P = .003)3 

less-ascites-red

Fewer paracenteses

with 1 paracentesis procedure required to treat ascites following placement of the VIATORR® Device, compared to 10 procedures with paracentesis treatment alone3

Not allowed icon

No increase in the risk of hepatic encephalopathy

at 1 year, compared to large volume paracenteses (LVP) and albumin infusion (P = .868)3 

Related to this product 

a. Based on benchtop data on file.
b. Refers to GORE® VIATORR® TIPS Endoprosthesis part numbers starting with PT10-
c. Data on file, based on bench-top testing that showed less than or equal to 1.0 mm diameter change over a 10 year design life.
d. Historical data from GORE® VIATORR® TIPS Endoprosthesis and GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion.
e. For a combined group of patients with Child-Pugh C (CP-C) score ≤13 or Child-Pugh B with active bleeding (CP-B + AB) at diagnostic endoscopy.
f. One-year actuarial probability of remaining free of failure to control bleeding and of variceal rebleeding.

  1. Boike JR, Thornburg BG, Asrani SK, et al. North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension. Clinical Gastroenterology and Hepatology. 2022;20(8):1636-1662.e36.  
  2. Bureau C, Pagan JCG, Layrargues GP, et al. Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long term results of a randomized multicentre study. Liver International 2007;27(6):742-747.
  3. Bureau C, Thabut D, Oberti F, et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology 2017;152(1):157-163.
  4. García-Pagán JC, Caca K, Bureau C, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. The New England Journal of Medicine 2010;362(25):2370-2379.  
IFU Consult instructions

Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. RXOnly

INDICATIONS FOR USE IN EUROPE: The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion is indicated for use in the treatment of portal hypertension and its complications such as variceal bleeding and ascites which recurs despite conventional treatment.

CONTRAINDICATIONS: There are no known contraindications for this device. 

Product may not be available in all countries. Please check with your Gore representative for availability.
25PL2100-EN04 MAT-0527-3